- Home
- KPLT vs INMB Comparison
KPLT vs INMB Comparison
Compare KPLT & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPLT
- INMB
- Stock Information
- Founded
- KPLT 2012
- INMB 2015
- Country
- KPLT United States
- INMB United States
- Employees
- KPLT N/A
- INMB N/A
- Industry
- KPLT Diversified Commercial Services
- INMB Biotechnology: Pharmaceutical Preparations
- Sector
- KPLT Consumer Discretionary
- INMB Health Care
- Exchange
- KPLT Nasdaq
- INMB Nasdaq
- Market Cap
- KPLT 52.2M
- INMB 49.2M
- IPO Year
- KPLT N/A
- INMB 2019
- Fundamental
- Price
- KPLT $5.75
- INMB $1.51
- Analyst Decision
- KPLT Hold
- INMB Hold
- Analyst Count
- KPLT 1
- INMB 3
- Target Price
- KPLT $10.00
- INMB $4.30
- AVG Volume (30 Days)
- KPLT 128.6K
- INMB 363.1K
- Earning Date
- KPLT 11-12-2025
- INMB 10-30-2025
- Dividend Yield
- KPLT N/A
- INMB N/A
- EPS Growth
- KPLT N/A
- INMB N/A
- EPS
- KPLT N/A
- INMB N/A
- Revenue
- KPLT $280,839,000.00
- INMB $50,000.00
- Revenue This Year
- KPLT $22.88
- INMB $191.43
- Revenue Next Year
- KPLT $10.98
- INMB $12,299.51
- P/E Ratio
- KPLT N/A
- INMB N/A
- Revenue Growth
- KPLT 16.15
- INMB 19.05
- 52 Week Low
- KPLT $5.08
- INMB $1.38
- 52 Week High
- KPLT $24.34
- INMB $11.64
- Technical
- Relative Strength Index (RSI)
- KPLT 25.89
- INMB 37.63
- Support Level
- KPLT $5.50
- INMB $1.38
- Resistance Level
- KPLT $6.43
- INMB $1.62
- Average True Range (ATR)
- KPLT 0.93
- INMB 0.10
- MACD
- KPLT -0.12
- INMB 0.00
- Stochastic Oscillator
- KPLT 8.63
- INMB 32.41
About KPLT Katapult Holdings Inc.
Katapult Holdings Inc. is a technology-driven lease-to-own platform that integrates with omni-channel retailers and e-commerce platforms to power the purchase of everyday durable goods for underserved U.S. non-prime consumers. It is an e-commerce-focused FinTech company offering a lease-purchase solution to consumers and enabling essential transactions at the merchant point of sale. Katapult is associated with hundreds of retailers across the United States.
About INMB INmune Bio Inc. Common stock
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.